IMAGE: OCTAPHARMA USA TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) OFFICE OF ORPHAN PRODUCTS DEVELOPMENT (OOPD) HAS AWARDED SEVEN YEARS OF MARKETING EXCLUSIVITY FOR OCTAGAM® 10% [IMMUNE GLOBULIN INTRAVENOUS (HUMAN)], THE FIRST AND ONLY INTRAVENOUS IMMUNOGLOBULIN (IVIG) TO BE INDICATED FOR THE TREATMENT OF ADULT DERMATOMYOSITIS (DM). CREDIT: OCTAPHARMA USA FDA Orphan Drug...
